Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selective Activation of the Adrenomedullin Receptors in Migraine
NCT07451769Recruiting
- Sponsor
- Dansk Hovedpinecenter
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial in migraine comparing Adrenomedullin with Placebo (2 arms). Primary endpoint: Incidence of migraine attacks at 12 hours. Started Mar 2026; status: recruiting.
02
Drugs
fispemifene
03
Conditions
migraine
Beyond the preview
Go deeper on NCT07451769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07451769.